Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue—
Net Income-$2.73M-$2.73MN/M vs Q1 2023 EPS Diluted-$1.11-$1.11N/M vs Q1 2023 Operating Income-$2,809,598N/M Operating Cash Flow-$2,048,884N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 10, 2024 · 40 d after period end